LILRB4/CD85k/ILT3 蛋白, Human (Biotinylated, HEK293, His-Avi)

The LILRB4/CD85k/ILT3 protein is a key inhibitory receptor that plays a key role in immune regulation and tolerance. As a receptor for FN1, apolipoprotein APOE, and ALCAM/CD166, it inhibits receptor-mediated phosphorylation, intracellular calcium mobilization, and FCGR1A/CD64-mediated monocyte activation, thereby reducing TNF production. LILRB4/CD85k/ILT3 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived LILRB4/CD85k/ILT3 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of LILRB4/CD85k/ILT3 Protein, Human (Biotinylated, HEK293, His-Avi) is 236 a.a., with molecular weight of 35-45 kDa.

LILRB4/CD85k/ILT3 是一种抑制性受体，在免疫调节和免疫耐受的建立中发挥着关键作用。该蛋白作为 FN1、载脂蛋白 APOE 和 ALCAM/CD166 的受体，参与多种细胞过程。它抑制受体介导的细胞蛋白磷酸化和细胞内钙离子的动员，并进一步下调 FCGR1A/CD64 介导的单核细胞活化，导致 TNF 产生减少。此外，LILRB4/ILT3 会阻碍 T 细胞增殖，诱导无反应性，抑制产生 IFNG 的 CD8+ 细胞毒性 T 细胞的分化，并促进 CD8+ T 抑制细胞的生成。它诱导树突状细胞上 CD86 上调，并干扰 TNFRSF5 信号传导和 NF-kappa-B 上调。抑制作用至少部分是通过与 FN1 和磷酸酶 PTPN6 的相互作用介导的。

Measured by its binding ability in a functional ELISA. When immobilized Anti-LILRB4 Antibody at 1μg/ml (100μl/Well), can bind Biotinylated Human LILRB4 and the EC₅₀ is < 10 ng/mL.

Human

HEK293

C-Avi;C-His

Q8NHJ6 (Q22-H257)

11006  [NCBI]

35-45 kDa

Greater than 95% as determined by Tris-Bis PAGE.

无菌粉末.

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Normally 5% trehalose is added as protectant before lyophilization.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.